+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis



Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis



Gastroenterology 130(6): 1661-1669



Hepatic steatosis is frequent in chronic hepatitis C. Several mechanisms might be implicated, including metabolic cofactors and direct viral effects on intracellular lipid pathways. In a transgenic mouse model, hepatitis C virus (HCV) was shown to inhibit microsomal triglyceride transfer protein (MTP) activity, which is essential for hepatic lipoprotein assembly and secretion. No data are available on liver MTP activity in HCV-infected patients. We therefore investigated liver MTP gene expression and its lipid transfer activity in untreated cases infected with the major HCV genotypes showing variable degrees of hepatic steatosis. MTP messenger RNA (mRNA) levels were measured by real-time polymerase chain reaction, and MTP activity was assessed by fluorescent assay in liver biopsy specimens of 58 HCV-positive patients. A set of metabolic and serum lipid markers was also measured at the time of liver biopsies. MTP mRNA levels showed a statistically significant (P = .001) inverse correlation with the degree of steatosis, independently of the HCV genotype. MTP mRNA levels also had an inverse correlation with serum insulin (P = .0002), homeostasis model assessment-insulin resistance (HOMA-IR) (P = .005), and body mass index (P = .02) in patients with HCV-1 and HCV-2 and with serum HCV-RNA (P = .02) in HCV-3 patients. Liver MTP-specific activity was significantly reduced in HCV-3 patients compared with those with other HCV genotypes (P = .004) and correlated with reduced serum cholesterol, apo B, and low-density lipoproteins. MTP may play a central role in HCV-related steatosis, being modulated by different genotype-specific mechanisms, mainly hyperinsulinemia in non-HCV-3 patients, and more profound and direct virus-related effects in HCV-3-infected individuals.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012268507

Download citation: RISBibTeXText

PMID: 16697730

DOI: 10.1053/j.gastro.2006.02.035


Related references

Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats. Journal of Hepatology 36(2): 157-162, 2002

Lack of association between microsomal triglyceride transfer protein gene polymorphism and liver steatosis in HCV-infected patients. Molecular Genetics and Metabolism 88(2): 196-198, 2006

Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 43(8): 995-999, 2000

Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP). Nutrition and Metabolism 7: 13, 2010

Microsomal triglyceride transfer protein polymorphism (-493G/T) is associated with hepatic steatosis in patients with chronic hepatitis C. Liver International 29(4): 557-565, 2009

Targeting L-Fabp attenuates Steatosis and Prevents Hepatic Fibrosis in Mice With Liver Specific Microsomal Triglyceride Transfer Protein Knockout (Mttp-Lko) By Changing Lipid Droplet Metabolism and Inducing Autophagy. Gastroenterology 150(4): S1025-S1026, 2016

Genetic variation in the microsomal triglyceride transfer protein (-493G/T) is associated with hepatic steatosis in patients infected with hepatitis C virus. Bmc Infectious Diseases 17(1): 235, 2017

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. Faseb Journal 16(2): 185-194, 2002

Prevention of hepatic fibrosis with liver microsomal triglyceride transfer protein deletion in liver fatty acid binding protein null mice. Hepatology 65(3): 836-852, 2017

Triglyceride and phospholipid binding to the bovine liver microsomal triglyceride transfer protein. FASEB Journal 7(7): A1268, 1993

Novel findings for the development of drug therapy for various liver diseases: Liver microsomal triglyceride transfer protein activator may be a possible therapeutic agent in non-alcoholic steatohepatitis. Journal of Pharmacological Sciences 115(3): 270-273, 2011

Crystallization of microsomal triglyceride transfer protein from bovine liver. Acta Crystallographica. Section D Biological Crystallography 52(Pt 1): 224-225, 1996

Purification and crystallization of microsomal triglyceride transfer protein from bovine liver. FASEB Journal 9(6): A1497, 1995

Microsomal triglyceride transfer protein and nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology 5(2): 245-251, 2011

4.P.262 Regulatory factor of microsomal triglyceride transfer protein (Mtp) activity in liver. Atherosclerosis 134(1-2): 351, 1997